HOUSTON, TX., September 9, 2019 — GREFFEX, INC. won a contract of up to $18.9 million with the National Institute of Health’s National Institute for Allergy and Infectious Diseases to develop and exploit its GreVac(TM) Plug-And-Play Technology to Expedite the Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases to target emerging infectious threats, whether natural or man-made.
GreVac(TM) vaccines are based upon GREFFEX’s proprietary GreGT Genetic Engineering Technology as a fast and flexible plug-and-play vaccine architecture of fully deleted helper virus- independent adenoviral vectors of rare serotypes. The proprietary GreGT platform has been built upon two independently modifiable components to provide broad gene transfer applications.
The GreVac(TM) system incorporates versatility and speed to complement and ultimately change the present paradigm of immune protection against infectious diseases with a high eruption potential from the stockpiling of potential vaccine candidates to the just-in-time production of specific vaccines.
With support by the present NIH contract, GREFFEX expects to advance the development of two of its GreVac(TM) influenza vaccines through clinical trials. The activity of a vaccine directed against a highly pathogenic avian influenza will be compared to a novel universal influenza vaccine. This research initiative is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract HHS-NIH-NIAID-BAA2018 (BAA-2018 Omnibus Broad Agency Announcement: Research Area 2 (DMID) – Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases).